4 things to know about biopharmaceutical efforts to fight cancer

A recent study published in Nature is a profound reminder of how far we’ve come in the fight against cancer. Authors of the study, which examined the long-term effects of CAR-T cell therapy,...
Read More
What you need to know about newly authorized COVID-19 antiviral treatments

In December 2021, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for the first two oral antivirals for the treatment of certain COVID-19 patients. These...
Read More
Guest post: Joining forces to combat the COVID-19 mental health crisis

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...
Read More
PhRMA submits comments urging CMS to withdraw coverage proposal

In comments submitted this week, PhRMA urged the Centers for Medicare & Medicaid Services (CMS) to withdraw its proposed national coverage determination (NCD) for monoclonal antibodies (mAbs) for the...
Read More
The importance of timely PDUFA and BsUFA reauthorization

Today, PhRMA, along with the U.S. Food and Drug Administration (FDA) and other industry trade associations, will be participating in a congressional hearing with the House Committee on Energy and...
Read More
Research and development continues long after a medicine is initially approved

The government’s flawed price setting plan under the Build Back Better Act will significantly upend the biopharmaceutical research and development (R&D) process, risking important advances in patient...
Read More
Protecting U.S. innovation abroad to support economic and pandemic recovery

PhRMA’s recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2022 Special 301 Report reinforce how the United States can confirm its strong commitment to defend...
Read More
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients

The U.S. Food and Drug Administration (FDA) approved a total of 60 new drugs in 2021. A new report from the FDA catalogs 50 new approvals by the Center for Drug Evaluation and Research (CDER)....
Read More
ICYMI: New report demonstrates growing global impact of antimicrobial resistance

New research published in The Lancet shows for the first time the global impact of antimicrobial resistance (AMR), which poses an increasingly serious threat to human health around the world. The...
Read More
New data show continued decline in death rates for cancer patients related to treatment advances

According to a new report from American Cancer Society (ACS), death rates for cancer patients in the United States continue to decrease. Each year, ACS details a range of incidence, mortality and...
Read More